Skip to main content

Vyepti (eptinezumab)

Lundbeck's VYEPTI Hits 60% Improvement in Phase IV THRIVE Trial

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

Trial enrolled 164 adults who had failed one prior CGRP preventive treatment

The 24-week, open-label, multicenter trial (NCT06701526) was conducted in the United States and enrolled 164 adults with at least eight monthly migraine days who had previously used either a subcutaneous anti-CGRP monoclonal antibody or a preventive gepant, but had not received eptinezumab. Participants started on 100 mg of eptinezumab, escalating to 300 mg at week 12, with 147 receiving both infusions; 84% (138/164) completed the trial.

Lundbeck Wins Japan Approval for Migraine Drug Vyepti, First Solo Launch

Valby, Denmark – – September 18, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.

MHLW clears the only IV CGRP-targeted migraine preventive on the market

Eptinezumab remains the sole intravenous CGRP-targeted therapy approved for migraine prevention, now available in more than 30 markets worldwide following the Japanese clearance. The drug was first approved by the U.S. FDA in February 2020, followed by the European Commission in January 2022 and, most recently, South Korea.